Zanamivir

Scientific Name:	Zanamivir
Brand Name:	Relenza
Company Owner:	Glaxosmithkline
Mechanism Of Action	The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
Description of the Drug:	Zanamivir is a neuraminidase inhibitor used to treat influenza A and B.
Protein Data Bank:	https://www.rcsb.org/structure/2QWE https://www.rcsb.org/structure/3SAN https://www.rcsb.org/structure/4WA5 https://www.rcsb.org/structure/4MWR https://www.rcsb.org/structure/2F0Z https://www.rcsb.org/structure/2CML https://www.rcsb.org/structure/1NNC https://www.rcsb.org/structure/2YA7 https://www.rcsb.org/structure/4MWX https://www.rcsb.org/structure/1V3E https://www.rcsb.org/structure/6EKU https://www.rcsb.org/structure/6HCX https://www.rcsb.org/structure/4B7N https://www.rcsb.org/structure/3TI5 https://www.rcsb.org/structure/4CPN https://www.rcsb.org/structure/1A4G https://www.rcsb.org/structure/7FGC https://www.rcsb.org/structure/4B7Q https://www.rcsb.org/structure/4I00 https://www.rcsb.org/structure/7U4G https://www.rcsb.org/structure/3CKZ https://www.rcsb.org/structure/3B7E https://www.rcsb.org/structure/2HTQ https://www.rcsb.org/structure/5L17 https://www.rcsb.org/structure/3TIC

Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00558

Drugs A - Z